PTH and hypophosphatemia: Bellini and colleagues reported the case of a 64 years-old patient with mRCC treated with sorafenib (400 mg b.i.d. orally), who developed hypophosphatemia after 1 month of treatment associated with a decrease in serum calcium and elevated PTH levels [84].